Drugs / BM-MNC

Trials 5 · a red edge is where a trial was stopped

20082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT03943940 Apr → Dec 2019 type 2 diabetes mellitus Van Hanh General Hospital Unknown No outcome recorded
Phase 1/2 NCT04501341 Mar 2016 → Dec 2021 type 2 diabetes mellitus Indonesia University Unknown No outcome recorded
Phase 1/2 NCT00767260 Mar 2008 → Mar 2012 type 2 diabetes mellitus Fuzhou General Hospital Completed No outcome recorded
Phase 1/2 NCT00713934 Jan 2008 → Jan 2009 cirrhosis of liver, disease related to hematopoietic stem cell transplant Royan Institute Completed No outcome recorded
Phase 1/2 NCT00677404 Jan 2008 → Oct 2009 limb ischemia, peripheral arterial disease Royan Institute Completed No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2/3 NCT02454231 Comparator Sep 2009 → May 2015 limb ischemia University of Florence Completed No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 7 sources stand behind the page.

FieldValueCited text
Known as BM MNC “autologous BM MNC [without G-CSF (MNC-G-CSF) or combined with G-CSF administration for 5 days following transplantation (MNC+G-CSF)]” PMID 20078390 Oct 2010
6

NCT00677404

NCT00713934

NCT03943940

NCT00767260

NCT02454231

NCT04501341

Known as BM-MNCs “The investigators designed a randomized clinical trial (stem cell emergency life threatening arteriopathy or SCELTA) to compare the therapeutic efficacy of the auto-transplant...” NCT02454231
2

“Autologous bone marrow mononuclear cells (BM-MNCs) and allogeneic umbilical cord tissue-derived mesenchymal stem cells (UC-MSCs) under sterile conditions to treat this disease.” NCT03943940

“Bone-marrow mononuclear cells (BM-MNCs) and umbilical-cord tissue-derived mesenchymal stem cells (UC-MSCs) via its immunomodulatory properties” NCT04501341

Known as bone marrow mononuclear cells “Autologous bone marrow mononuclear cells (BM-MNCs) and allogeneic umbilical cord tissue-derived mesenchymal stem cells (UC-MSCs) under sterile conditions to treat this disease.” NCT03943940
2

“Autologous bone-marrow mononuclear cells infused to the main blood vessels that supply the pancreas” NCT04501341

“implantation of autologous bone marrow mononuclear cellsPMID 20078390 Oct 2010

Modality Cell therapy “autologous transplantation of mononuclear cells” NCT00677404
Route Intramuscular “is intramuscularly injected” NCT00677404